Evidence map›Paper›PMID 28771480›Full record

ArticlePLoS neglected tropical diseases2017

The global burden of disease study 2013: What does it mean for the NTDs?

Jennifer R Herricks, Peter J Hotez, Valentine Wanga, Luc E Coffeng, Juanita A Haagsma, María-Gloria Basáñez, Geoffrey Buckle, Christine M Budke, Hélène Carabin, Eric M Fèvre and 11 more

3 registry-linked trialsAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 125 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03517462 nacompletednot on this mapstarted 2018, after this paper: background citation

Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2018 to 2019Enrolled231ConditionsOnchocerciasisArmsIvermectin 3Mg Tab
NCT04188301 phase2completednot on this mapstarted 2019, after this paper: background citation

Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2019 to 2022Enrolled154ConditionsOnchocerciasisArmsIVM w/ ALB, Single dose of IDA, Three daily doses of IDA
NCT06070116 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2024 to 2026Enrolled300ConditionsOnchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca InfectionArmsIvermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole, Moxidectin + Diethylcarbamazine + Albendazole
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Spatial and seasonal dynamics ofParasite epidemiology and control · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jennifer R HerricksDepartment of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Peter J HotezDepartment of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.ORCID 0000-0001-8770-1042
Valentine WangaInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Luc E CoffengInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Juanita A HaagsmaInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
María-Gloria BasáñezLondon Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
Geoffrey BuckleUniversity of California, San Francisco, San Francisco, California, United States of America.
Christine M BudkeDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States of America.
Hélène CarabinDepartment of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
Eric M FèvreInternational Livestock Research Institute, Nairobi, Kenya.
Thomas FürstSchool of Public Health, Imperial College London, London, United Kingdom.
Yara A HalasaSchneider Institutes for Health Policy, Brandeis University, Waltham, Massachusetts, United States of America.
Charles H KingCenter for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Michele E MurdochDepartment of Dermatology, Watford General Hospital, Watford, Herts, United Kingdom.
Kapa D RamaiahConsultant on Lymphatic Filariasis, Tagore Nagar, Pondicherry, India.
Donald S ShepardSchneider Institutes for Health Policy, Brandeis University, Waltham, Massachusetts, United States of America.
Wilma A StolkInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Eduardo A UndurragaSchneider Institutes for Health Policy, Brandeis University, Waltham, Massachusetts, United States of America.
Jeffrey D StanawayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Mohsen NaghaviInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Christopher J L MurrayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.

Funding

Biotechnology and Biological Sciences Research Council BB/L019019/1Medical Research Council G1100783
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Global HealthTropical MedicineBacterial InfectionsCommunicable Disease ControlCost of IllnessHumansIncidenceNeglected DiseasesParasitic DiseasesPrevalenceQuality-Adjusted Life YearsRisk FactorsVirus Diseases

Identifiers

PMID28771480
PMCPMC5542388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.